Search details
1.
Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity.
Cell
; 177(7): 1701-1713.e16, 2019 06 13.
Article
in English
| MEDLINE | ID: mdl-31155232
2.
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells.
Cell
; 175(7): 1731-1743.e13, 2018 12 13.
Article
in English
| MEDLINE | ID: mdl-30503213
3.
Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis.
Nature
; 588(7836): 146-150, 2020 12.
Article
in English
| MEDLINE | ID: mdl-32726800
4.
Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123.
Nat Biotechnol
; 41(9): 1296-1306, 2023 09.
Article
in English
| MEDLINE | ID: mdl-36635380
5.
Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant.
Cell Rep Med
; 3(10): 100783, 2022 10 18.
Article
in English
| MEDLINE | ID: mdl-36260981
6.
CD73-Mediated Immunosuppression Is Linked to a Specific Fibroblast Population That Paves the Way for New Therapy in Breast Cancer.
Cancers (Basel)
; 13(23)2021 Nov 23.
Article
in English
| MEDLINE | ID: mdl-34884993
7.
Targeting MICA/B with cytotoxic therapeutic antibodies leads to tumor control.
Open Res Eur
; 1: 107, 2021.
Article
in English
| MEDLINE | ID: mdl-35967081
8.
A novel targeted immunotherapy for CTCL is on its way: Anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies.
Oncoimmunology
; 4(9): e1022306, 2015 Sep.
Article
in English
| MEDLINE | ID: mdl-26405593
9.
Identification of druggable inhibitory immune checkpoints on Natural Killer cells in COVID-19.
Cell Mol Immunol
; 17(9): 995-997, 2020 09.
Article
in English
| MEDLINE | ID: mdl-32612152
Results
1 -
9
de 9
1
Next >
>>